At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 80 enrolled
Drug / intervention
Tocilizumab 20 Mg/mL Intravenous Solution +1 moredrug
Likely dose
Tocilizumab 20 Mg/mL Intravenous Solutionfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Interleukin-6 Receptor Antibodies for Modulating the Systemic Inflammatory Response After Out-of-Hospital Cardiac Arrest - a Randomized Clinical Trial
In Brief
A Phase 2 clinical trial evaluating Tocilizumab 20 Mg/mL Intravenous Solution and isotonic saline for Heart Arrest and 2 related conditions. Completed, enrolled 80 participants across 1 site.
Detailed Summary
Resuscitated cardiac arrest is associated with a systemic inflammatory response that is directly associated with poor prognosis. Inhibition of the IL-6 mediated immune response may potentially inhibit the systemic inflammatory response, potentially improving the prognosis of these severely ill patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesDenmark
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
Enrollment StartMar 2019
First PostedMar 2019
Primary CompletionDec 2019
Study CompletionJun 2020
TodayJul 2026
First PostedMar 5, 2019
Enrollment StartMar 4, 2019
Primary CompletionDec 23, 2019
Study CompletionJun 30, 2020
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 7.3 years ago
Interventions
Tocilizumab 20 Mg/mL Intravenous Solutiondrug
Tocilizumab is suspended in isotonic saline to a total volume of 100mL prior to infusion
isotonic salinedrug
A one hour infusion of 100mL isotonic saline